Rocket Pharmaceuticals Stock Falls 3% After Earnings — Commercial Preparations Push Administrative Costs Higher

Research costs fell, but Rocket posted a $49.2 million quarterly loss as it prepared for commercial patient treatment.

Share
Rocket Pharmaceuticals Stock Falls 3% After Earnings — Commercial Preparations Push Administrative Costs Higher

Rocket Pharmaceuticals, which develops gene therapies for rare, often fatal diseases, fell 2.9% to $2.32 in Friday trading, as of 10:41 AM ET, losing $8 million in market value. The decline followed Thursday's earnings update, with a quarterly net loss of $49.2 million as the company prepared for commercial patient treatment.

Commercial Costs Rise, Research Costs Fall

Compared with the $18.4 million recorded a year earlier, Rocket's latest administrative expenses were higher at $19.8 million. The company attributed most of the increase to commercial preparations and obligations after marketing.

Against a year-earlier total of $34.1 million, research spending declined to $31.2 million. Rocket attributed the decline mainly to lower manufacturing costs and employee compensation.

Rocket said in Thursday's earnings update that its cash and investments should fund planned operations through a period of clinical development and preparations for commercialization.

Kresladi Moves Toward Patient Treatment

Kresladi became commercially ready earlier in October, and treatment centers were activated to bring patients onboard. The therapy addresses leukocyte adhesion deficiency-I, a rare immune disorder.

Rocket's gene therapies use modified viruses to put a functioning gene copy into patients' cells. Its principal development focus is rare heart disease, including Danon disease, a form of arrhythmogenic cardiomyopathy and a form of dilated cardiomyopathy.

Rocket arranged a credit facility of up to $150 million with Hercules Capital, the lender supporting its cardiovascular programs. The company produces clinical supply at its 103,720-square-foot facility in Cranbury, New Jersey.

Rocket has paused its Fanconi anemia and pyruvate kinase deficiency programs and is seeking partners for them.

A Decline On A Difficult Year

Rocket shares were down 32% year to date at Thursday's close, compared with an 11% gain for the S&P 500. In Friday trading, the stock was on pace for its largest one-day decline since Thursday, with a total market value of about $255 million.

The Danon disease trial remains a development priority. Rocket CEO Gaurav Shah said, "our priority is to complete dosing by mid-2027."

Rocket expects results from its Danon disease trial in mid-2028.

Sources

More on Rocket Pharmaceuticals

All Rocket Pharmaceuticals (RCKT) coverage →